{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:31:40Z","timestamp":1790710300927,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FA 441\/4-1"],"award-info":[{"award-number":["FA 441\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FA 441\/4-1"],"award-info":[{"award-number":["FA 441\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2761-x","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T08:16:24Z","timestamp":1531728984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Friederike","family":"Schaub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hoerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Felsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marouan","family":"Zarrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Fauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"2761_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0161-6420(87)33443-8","volume":"94","author":"BM Glaser","year":"1987","unstructured":"Glaser BM, Cardin A, Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology. 1987;94:327\u201332.","journal-title":"Ophthalmology"},{"key":"2761_CR2","doi-asserted-by":"publisher","first-page":"206385","DOI":"10.5402\/2012\/206385","volume":"2012","author":"JC Pastor","year":"2012","unstructured":"Pastor JC, Fernandez I, Coco RM, Sanabria MR, Rodriguez dR, Pinon RM, et al. Variations in functional and anatomical outcomes and in proliferative vitreoretinopathy rate along a prospective collaborative study on primary Rhegmatogenous retinal detachments: the retina 1 project-report 4. ISRN Ophthalmol. 2012;2012:206385.","journal-title":"ISRN Ophthalmol."},{"key":"2761_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/bjo.2007.131540","volume":"92","author":"DJ de Silva","year":"2008","unstructured":"de Silva DJ, Kwan A, Bunce C, Bainbridge J. Predicting visual outcome following retinectomy for retinal detachment. Br J Ophthalmol. 2008;92:954\u20138.","journal-title":"Br J Ophthalmol."},{"key":"2761_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.preteyeres.2004.07.001","volume":"24","author":"C Guidry","year":"2005","unstructured":"Guidry C. The role of Muller cells in fibrocontractive retinal disorders. Prog Retin Eye Res. 2005;24:75\u201386.","journal-title":"Prog Retin Eye Res"},{"key":"2761_CR5","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1167\/iovs.07-0086","volume":"48","author":"H Lee","year":"2007","unstructured":"Lee H, O'Meara SJ, O\u2019Brien C, Kane R. The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2007;48:4291\u20139.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2761_CR6","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.1167\/iovs.09-3621","volume":"50","author":"SK Parapuram","year":"2009","unstructured":"Parapuram SK, Chang B, Li L, Hartung RA, Chalam KV, Nair-Menon JU, et al. Differential effects of TGFbeta and vitreous on the transformation of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2009;50:5965\u201374.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2761_CR7","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","volume":"108","author":"RH Asaria","year":"2001","unstructured":"Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179\u201383.","journal-title":"Ophthalmology"},{"key":"2761_CR8","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0161-6420(01)00553-X","volume":"108","author":"RH Asaria","year":"2001","unstructured":"Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Luthert PJ, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology. 2001;108:1184\u20136.","journal-title":"Ophthalmology"},{"key":"2761_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","volume":"114","author":"L Wickham","year":"2007","unstructured":"Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114:698\u2013704.","journal-title":"Ophthalmology"},{"key":"2761_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","volume":"126","author":"P Wiedemann","year":"1998","unstructured":"Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998;126:550\u20139.","journal-title":"Am J Ophthalmol."},{"key":"2761_CR11","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.ophtha.2004.05.036","volume":"111","author":"DG Charteris","year":"2004","unstructured":"Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111:2240\u20135.","journal-title":"Ophthalmology"},{"key":"2761_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/bjophthalmol-2014-305263","volume":"99","author":"J Rojas","year":"2015","unstructured":"Rojas J, Fernandez I, Pastor JC, MacLaren RE, Ramkissoon Y, Harsum S, et al. Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables. Br J Ophthalmol. 2015;99:41\u20138.","journal-title":"Br J Ophthalmol."},{"key":"2761_CR13","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1097\/IAE.0b013e31828991ea","volume":"33","author":"A Sala-Puigdollers","year":"2013","unstructured":"Sala-Puigdollers A, Fern\u00e1ndez I, Coco RM, Sanabria MR, Rodr\u00edguez de la R\u00faa E, Ruiz-Moreno JM, et al. External validation of existing formulas to predict the risk of developing proliferative vitreoretinopathy: the retina 1 project; report 5. Retina. 2013;33:1519\u201327.","journal-title":"Retina"},{"key":"2761_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/bjophthalmol-2012-302636","volume":"97","author":"R Hoerster","year":"2013","unstructured":"Hoerster R, Hermann MM, Rosentreter A, Muether PS, Kirchhof B, Fauser S. Profibrotic cytokines in aqueous humour correlate with aqueous flare in patients with rhegmatogenous retinal detachment. Br J Ophthalmol. 2013;97:450\u20133.","journal-title":"Br J Ophthalmol."},{"key":"2761_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/IAE.0b013e3182173753","volume":"32","author":"S Schroder","year":"2012","unstructured":"Schroder S, Muether PS, Caramoy A, Hahn M, Abdel-Salam M, Diestelhorst M, et al. Anterior chamber aqueous flare is a strong predictor for proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. Retina. 2012;32:38\u201342.","journal-title":"Retina"},{"issue":"4","key":"2761_CR16","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1111\/aos.13254","volume":"95","author":"JB Conart","year":"2017","unstructured":"Conart JB, Kurun S, Ameloot F, Trechot F, Leroy B, Berrod JP. Validity of aqueous flare measurement in predicting proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. Acta Ophthalmol. 2017;95(4):e278\u201383.","journal-title":"Acta Ophthalmol"},{"key":"2761_CR17","first-page":"CD006421","volume":"1","author":"V Sundaram","year":"2013","unstructured":"Sundaram V, Barsam A, Virgili G. Intravitreal low molecular weight heparin and 5-fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev. 2013;1:CD006421.","journal-title":"Cochrane Database Syst Rev."},{"key":"2761_CR18","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1097\/00006982-199212031-00015","volume":"12","author":"MS Blumenkranz","year":"1992","unstructured":"Blumenkranz MS, Hartzer MK, Iverson D. An overview of potential applications of heparin in vitreoretinal surgery. Retina. 1992;12:S71\u20134.","journal-title":"Retina"},{"key":"2761_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0161-6420(84)34318-4","volume":"91","author":"M Blumenkranz","year":"1984","unstructured":"Blumenkranz M, Hernandez E, Ophir A, Norton EW. 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology. 1984;91:122\u201330.","journal-title":"Ophthalmology"},{"key":"2761_CR20","doi-asserted-by":"crossref","unstructured":"The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983;90:121\u2013125.","DOI":"10.1016\/S0161-6420(83)34588-7"},{"key":"2761_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0002-9394(14)76695-4","volume":"112","author":"R Machemer","year":"1991","unstructured":"Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159\u201365.","journal-title":"Am J Ophthalmol"},{"key":"2761_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/sim.4780090403","volume":"9","author":"MG Haviland","year":"1990","unstructured":"Haviland MG. Yates\u2019s correction for continuity and the analysis of 2 x 2 contingency tables. Stat Med. 1990;9:363\u20137.","journal-title":"Stat Med"},{"key":"2761_CR23","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/sim.3531","volume":"28","author":"S Lydersen","year":"2009","unstructured":"Lydersen S, Fagerland MW, Laake P. Recommended tests for association in 2 x 2 tables. Stat Med. 2009;28:1159\u201375.","journal-title":"Stat Med"},{"key":"2761_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/sim.4780030302","volume":"3","author":"A Donner","year":"1984","unstructured":"Donner A. Approaches to sample size estimation in the design of clinical trials--a review. Stat Med. 1984;3:199\u2013214.","journal-title":"Stat Med"},{"key":"2761_CR25","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00417-012-2007-7","volume":"250","author":"KR Koch","year":"2012","unstructured":"Koch KR, Hermann MM, Kirchhof B, Fauser S. Success rates of retinal detachment surgery: routine versus emergency setting. Graefes Arch Clin Exp Ophthalmol. 2012;250:1731\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"2761_CR26","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/j.0006-341X.1999.01286.x","volume":"55","author":"W Lehmacher","year":"1999","unstructured":"Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics. 1999;55:1286\u201390.","journal-title":"Biometrics"},{"key":"2761_CR27","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"2761_CR28","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/bjophthalmol-2011-300581","volume":"96","author":"D Mitry","year":"2012","unstructured":"Mitry D, Awan MA, Borooah S, Siddiqui MA, Brogan K, Fleck BW, et al. Surgical outcome and risk stratification for primary retinal detachment repair: results from the Scottish retinal detachment study. Br J Ophthalmol. 2012;96:730\u20134.","journal-title":"Br J Ophthalmol"},{"key":"2761_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0039-6257(98)00023-X","volume":"43","author":"JC Pastor","year":"1998","unstructured":"Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3\u201318.","journal-title":"Surv Ophthalmol"},{"key":"2761_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1350-9462(01)00023-4","volume":"21","author":"JC Pastor","year":"2002","unstructured":"Pastor JC, De La Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127\u201344.","journal-title":"Prog Retin Eye Res."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2761-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T15:37:55Z","timestamp":1569253075000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2761-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2761"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2761-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"24 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Before the start of the clinical trial, all necessary documentation has been submitted to the competent supreme federal authority for approval (Federal Institute for Drugs and Medical Products, Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte [BfArM]) and the local IRBs of all attending centers. Favorable opinions have been received (ethics committee of the medical faculty at the University of Cologne; IRB no. 16\u2013192). Written informed consent of participants is obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"384"}}